A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Vortioxetine Film-coated Tablet 10 mg relative to Brintellix 10 mg in healthy Thai volunteers under fasting condition

开始日期2025-07-11

申办/合作机构

Bio-innova Co., Ltd

CTRI/2024/09/073258

/ Not yet recruitingN/A

To assess the safety, effectiveness and utility of vortioxetine as initial line therapy in the Management of depression through an observational, multicenter Study - IMPRESS

开始日期2025-07-02

申办/合作机构

Torrent Pharmaceuticals Ltd.

NCT06604520

/ Recruiting临床2期IIT

Functional Neuroimaging to Examine Affective Symptoms and Cognition in Frontotemporal Dementia

The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are:
1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD?
2. Do mood symptoms and cognition improve following treatment with vortioxetine?
Researchers will also determine whether there are changes in the brain associated with vortioxetine treatment.
Participants will:
* Undergo a screening visit that involves clinical assessments and laboratory tests
* Undergo an initial brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (18F) Positron Emission Tomography (FDG PET) scan before starting treatment with vortioxetine
* Undergo memory and problem-solving tests before starting treatment with vortioxetine
* Undergo approximately 12 weeks of treatment with vortioxetine, during which time there will be regular contact and assessments with the study psychiatrist
* Undergo a repeat PET scan and repeat memory and problem-solving tests after 12 weeks of treatment with vortioxetine

开始日期2025-03-20

申办/合作机构

The Johns Hopkins University

[+2]

100 项与 HTR3 x 5-HT1B receptor 相关的临床结果

登录后查看更多信息

100 项与 HTR3 x 5-HT1B receptor 相关的转化医学

登录后查看更多信息

0 项与 HTR3 x 5-HT1B receptor 相关的专利（医药）

登录后查看更多信息

166

项与 HTR3 x 5-HT1B receptor 相关的文献（医药）

2025-05-01·Neurogastroenterology & Motility

Serotonin Receptors Polymorphisms Are Associated With Cyclic Vomiting Syndrome

Article

作者: Włodarczyk, Jakub ; Venkatesan, Thangam ; Binienda, Agata ; Patel, Milan ; Fichna, Jakub ; Salaga, Maciej

ABSTRACTBackgroundCyclic vomiting syndrome (CVS) is a disorder characterized by sudden, recurrent episodes of severe nausea and vomiting. The pathophysiology of CVS is not known but genetic factors that regulate emetic neurocircuitry have been proposed. The aim of this study was to investigate whether different variations in genes encoding serotonin receptors (HTRs) are associated with susceptibility to CVS and/or CVS symptoms.MethodsThis case–control study included 70 patients with CVS:16 male and 54 female, and 2504 healthy controls from the 1000 Genomes Project database. Single‐nucleotide polymorphisms (SNPs) in genes encoding serotonin receptors (HTR1B, HTR1D, HTR3B and HTR3C) and correlations between SNPs and the symptoms of CVS were determined.Key ResultsOur study discovered that patients with GG, AA and GG genotypes of HTR1B/D rs6296, rs6298 and rs6300, respectively, as well as the CC genotype of HTR3B rs176744 are associated with an increased risk (p < 0.001), whereas allele C in rs3788987 (HTR3B, p < 0.01) and allele A in rs6766410 (HTR3C, p < 0.05) were associated with a decreased risk of CVS. In addition, statistical analysis indicated that CVS patients with GA or AA genotypes of HTR1D rs676643 gene have a seven‐fold increase in risk of depression compared to patients with GG genotype (p < 0.01).Conclusions and InferencesOur study revealed for the first time that variations in 5‐HTR genes may contribute to CVS susceptibility and CVS‐related symptoms.

2025-05-01·Alcohol

Association between 5-HTRs gene polymorphism and alcohol use disorder in Han males from Yunnan, China

Article

作者: Zhong, Shurong ; Bao, Jianjun ; Gao, Changqing ; Yang, Xiaopei ; Wang, Yue ; Li, Kuan ; Peng, Jiahui ; Wei, Wei ; Zheng, Xinjian ; Zhao, Fei ; Zhang, Xulan ; Zhang, Ning

Alcohol use disorder (AUD) has become a very serious medical and social problem. It is found that genetic polymorphisms of the 5-hydroxytryptamine receptors (5-HTRs) genes were associated with the risk of AUD. However, the results are controversial among different ethnic groups. At present, the correlation between 5-HTRs gene polymorphism and AUD in Han population from Yunnan Province remains unclear. In this study, 13 single nucleotide polymorphisms (SNPs) of HTR1B, HTR2A, HTR3A, HTR3B and HTR7 were detected by universal fluorescent probe technique. The CT genotype frequency of HTR3A rs1062613 was significantly higher in AUD case group than that in control group (P = 0.037, OR = 2.193, 95% CI: 1.048-4.366). The study indicated that the genetic polymorphisms of 5-HTRs were significantly associated with risk of AUD in Han male from Yunnan, China. In addition, this study further demonstrated the impact of alcohol on human health, especially liver damage, by analyzing the blood biochemical indicators of patients with AUD and combining them with their medical history.

2025-04-01·CNS Neuroscience & Therapeutics

Characterization of the Molecular Mechanisms Underlying Lurasidone‐Induced Acute Manic Episodes in Bipolar Depression: A Network Pharmacology and Molecular Docking Approach

Article

作者: Wang, Lina ; Li, Chao ; Zhuo, Chuanjun ; Jia, Feng ; Yang, Lei ; Ma, Xiaoyan ; Zhang, Ying ; Zhang, Qiuyu ; Li, Ranli ; Tian, Hongjun

ABSTRACTBackgroundLurasidone monotherapy has been approved for the treatment of bipolar depression. However, several case reports have indicated treatment with lurasidone‐induced acute mania in people with bipolar depression. The mechanism by which this occurs remains to be elucidated.ObjectiveIn this study, we systematically explored the mechanism of action of lurasidone‐induced acute mania in bipolar depression using network pharmacology and molecular docking.MethodsPutative target genes for lurasidone were obtained from the GeneCards, PharmMapper, SwissTargetPrediction, and DrugBank databases. Targets for bipolar depression and acute mania were collected from the DisGeNET and GeneCards databases. A protein–protein interaction (PPI) network was built to screen the hub targets. The Bioinformatics platform and Database for Annotation, Visualization, and Integrated Discovery were used for the visualization of the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses of the top 20 core targets. The drug‐pathway‐target‐disease network was constructed using Cytoscape. Finally, molecular docking was performed to evaluate the binding affinity between lurasidone and potential targets.ResultsIn total, 327, 1253, and 429 targets of lurasidone, bipolar depression, and acute mania were identified, respectively. A topological analysis of the PPI network revealed the top 20 hub targets. Based on PPI, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes pathway analyses of the top 20 hub targets, lurasidone was found to induce acute manic episodes in people with bipolar depression by targeting the serotonergic synapse signaling pathway via MAOB, HTR1A, HTR2A, HTR3A, SLC18A2, HTR1B, and HTR7. Molecular docking revealed good binding affinities between lurasidone and these potential targets.ConclusionsThis study revealed that lurasidone may regulate the serotonergic synapse signaling pathway by interacting with the identified core targets MAOB, HTR1A, HTR2A, HTR3A, SLC18A2, HTR1B, and HTR7 to induce treatment‐emergent mania in people with bipolar depression. Our work provides a theoretical basis for the pharmacology of lurasidone‐induced acute mania in bipolar depression and further basic research.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。